Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec. 19, 2016 - Puma Biotechnology to Move Stock Exchange Listing to Nasdaq Ticker symbol to remain PBYI Read
- Dec. 8, 2016 - Puma Biotechnology Presents Interim Results of Phase II CONTROL trial of PB272 in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Read
- Dec. 7, 2016 - Puma Biotechnology Presents Results of Biomarker Analysis of Phase II trial of PB272 in Neoadjuvant treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Read
- Dec. 7, 2016 - Puma Biotechnology Presents Interim Results of Phase II trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Read
- Dec. 6, 2016 - Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States Read
- Nov. 14, 2016 - Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS) Read
- Nov. 9, 2016 - Puma Biotechnology Reports Third Quarter 2016 Financial Results Read
- Oct. 31, 2016 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference Read
- Oct. 25, 2016 - Puma Biotechnology Closes $172 Million Public Offering of Common Stock Read
- Oct. 21, 2016 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Share Read
- Oct. 19, 2016 - Puma Biotechnology Prices Public Offering of Common Stock Read
- Oct. 18, 2016 - Puma Biotechnology Announces Proposed Public Offering of Common Stock Read
- Sept. 20, 2016 - Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
- Aug. 22, 2016 - Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer in Europe Read
- Aug. 9, 2016 - Puma Biotechnology Reports Second Quarter 2016 Financial Results Read
- July 21, 2016 - Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
- July 21, 2016 - Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET trial) Read
- July 7, 2016 - Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine Read
- June 27, 2016 - Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer in Europe Read
- June 5, 2016 - Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting Read
- May 18, 2016 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting Read
- May 17, 2016 - Puma Biotechnology to Present at UBS Global Healthcare Conference Read
- May 10, 2016 - Puma Biotechnology Reports First Quarter 2016 Financial Results Read
- May 4, 2016 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference Read
- April 20, 2016 - Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016 Read
- April 14, 2016 - Puma Biotechnology’s NEfERT-T Phase II Study Published Online in JAMA Oncology Read
- March 28, 2016 - Puma Biotechnology Updates Timeline for Filing New Drug Application NDA Filing Currently Anticipated Mid-2016 Read
- March 18, 2016 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016 Read
- March 2, 2016 - Puma Biotechnology to Present at Cowen’s Health Care Conference Read
- Feb. 29, 2016 - Puma Biotechnology Reports Fourth Quarter and Full Year 2015 Financial Results Read
- Feb. 17, 2016 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference Read
- Feb. 16, 2016 - Puma Biotechnology Announces the Conclusion and Final Results of Eshelman’s Consent Solicitation Read
- Feb. 11, 2016 - Puma Biotechnology’s ExteNET Phase III Study Published Online in The Lancet Oncology Read
- Feb. 3, 2016 - Puma Biotechnology to Participate in Fireside Chat at Leerink Partners Global Healthcare Conference Read
- Jan. 8, 2016 - Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation Read
- Jan. 4, 2016 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Read